Free shipping on all orders over $ 500

LNP023 hydrochloride (Iptacopan HCl)

Cat. No. M10317
LNP023 hydrochloride (Iptacopan HCl) Structure
Synonym:

Iptacopan hydrochloride

Size Price Availability Quantity
5mg USD 380  USD380 In stock
10mg USD 650  USD650 In stock
25mg USD 1050  USD1050 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

Iptacopan (LNP023) hydrochloride is an orally bioavailable, highly potent and selective factor B inhibitor with an IC50 value of 10 nM. Iptacopan (LNP023) shows direct, reversible, and high-affinity binding to human factor B with a KD of 7.9 nM. LNP023 exhibits excellent selectivity over other proteases affording IC50 values of >30 μM across a panel of 41 human proteases, including the AP protein factor D (>100 μM).

In vivo, LNP023 (20-180 mg/kg; oral) prevents KRN (150 μL)-induced arthritis in mice and is effective upon prophylactic and therapeutic dosing in an experimental model of membranous nephropathy in rats.

Chemical Information
Molecular Weight 458.98
Formula C25H31ClN2O4
CAS Number 1646321-63-2
Solubility (25°C) DMSO ≥ 90 mg/mL
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month
Conversion of different model animals based on BSA (PMID: 27057123)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.

References

[1] Nello Mainolfi, et al. J Med Chem. Discovery of 4-((2 S,4 S)-4-Ethoxy-1-((5-methoxy-7-methyl-1 H-indol-4-yl)methyl)piperidin-2-yl)benzoic Acid (LNP023), a Factor B Inhibitor Specifically Designed To Be Applicable to Treating a Diverse Array of Complement Mediated Diseases

[2] Anna Schubart, et al. Proc Natl Acad Sci U S A. Small-molecule factor B inhibitor for the treatment of complement-mediated diseases

[3] Dimitrios C Mastellos, et al. Semin Hematol. Expanding Complement Therapeutics for the Treatment of Paroxysmal Nocturnal Hemoglobinuria

Related Complement System Products
P014

P014 is a C5 antibody/CFH fragment fusion protein that can be used in studies related to paroxysmal sleep hemoglobinuria (PNH) and thrombotic microangiopathy (TMA).

POT-4

POT-4 (AL-78898A), a Compstatin derivative, is a potent inhibitor of complement factor C3 activation.

TLQP-21

TLQP-21, a VGF-derived peptide endowed of endocrine and extraendocrine properties, is a potent G-protein-coupled receptor complement-3a receptor 1 (C3aR1) agonist (EC50: mouse TLQP-21=10.3 μM; human TLQP-21=68.8 μM).

N-((Allyloxy)carbonyl)-N-methyl-L-alanine

N-((Allyloxy)carbonyl)-N-methyl-L-alanine is a Alanine derivative.

C5a Receptor agonist, mouse, human

C5a Receptor agonist, mouse, human is a biological active peptide.

  Catalog
Abmole Inhibitor Catalog




Keywords: LNP023 hydrochloride (Iptacopan HCl), Iptacopan hydrochloride supplier, Complement System, inhibitors, activators


Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.